Pfizer’s arthritis drug can cut death risk in severe Covid patients

10:19 PM Jun 17, 2021 | IANS

New York: An arthritis drug — Tofacitinib — developed by US biopharmaceutical Pfizer has shown to be effective in reducing the risk of death or respiratory failure in hospitalised adult patients with Covid-19 pneumonia who were not on ventilation, according to a study.

Tofacitinib belongs to a class of drugs called Janus kinase (JAK) inhibitors. It is approved in the US to treat conditions including rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.


The efficacy of Tofacitinib was tested on 289 patients hospitalised with severe Covid across 15 locations in Brazil. Half of these patients received 10 mg twice daily plus standard of care which includes glucocorticoids, while the other half were prescribed placebo twice daily plus standard of care for up to 14 days.


Pfizer Covid-19 jabs found effective against Beta, Gamma variant

The results published in the New England Journal of Medicine showed that after 28 days, tofacitinib lowered the death or respiratory failure by 63 per cent. Among patients on tofacitinib, only 18.1 per cent had the incidence of death or respiratory failure compared to placebo (29 per cent).

Deaths in the tofacitinib group occurred in 2.8 per cent of patients and in 5.5 per cent of those in the placebo group. Serious side effects occurred in 14.1 percent in the tofacitinib group and in 12 percent in the placebo group.

"We are encouraged by the initial findings of our randomized trial of tofacitinib in patients hospitalised with Covid-19 pneumonia," said Otavio Berwanger, Director of the Academic Research Organisation, Hospital Israelita Albert Einstein, which coordinated the trial in collaboration with Pfizer.

UK regulator approves Pfizer/BioNTech vaccine for 12 to 15-year-old kids

"These results provide new information which indicates that the use of tofacitinib when added to standard of care, which includes glucocorticoids, may further reduce the risk of death or respiratory failure in this patient population," Berwanger added.

However, it is important to note that tofacitinib has not been approved or authorised for use by any regulatory authority worldwide for the treatment of Covid-19 and tofacitinib should not be used in patients with an active serious infection, the researchers said.

COVID-19 vaccine: Pfizer jab produces less antibodies against Delta variant of coronavirus, says Lancet study

(To receive our E-paper on whatsapp daily, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

(To view our epaper please Read Now. For all the latest News, Mumbai, Entertainment, Cricket, Business and Featured News updates, visit Free Press Journal. Also, follow us on Twitter and Instagram and do like our Facebook page for continuous updates on the go)